This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Distribution Variance of Focal Atrial Tachycardia Foci and Long-Term Outcomes After Ablation. We aimed to evaluate age differences in foci and factors influencing recurrence after radiofrequency catheter ablation in adult and juvenile patients with FAT. After a mean follow-up of 47.2 months, FAT recurred in 57 patients.
Expanding the potential patient population for pulsed field ablation, results from the SINGLE SHOT CHAMPION study suggest PFA might be just as good as cryoballoon ablation for patients with paroxysmal AFib. PFA has shown advantages in procedure time and safety, but its effectiveness is unproven compared to cryoballoon ablation.
a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024. milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. ,
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. Early recurrence of atrial tachyarrhythmia (ERAT) is commonly seen following catheter ablation of AF, with reported incidences of up to 61% in the first three months.
The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap System with electrographic flow (EGF) and newly released Ablacath Mapping Catheter basket mapping catheter to identify extra-pulmonary vein EGF sources. and may enroll up to 400 subjects across 20+ centers in the US and Europe.
Ablation index (AI)-guided pulmonary vein isolation (PVI) has enhanced procedural outcomes for atrial fibrillation (AF).1 1 However, patients with persistent AF present higher recurrence rates due to advanced atrial remodeling,2-3 represented by the left atrial low voltage area (LVA), compared to those with paroxysmal AF.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S.
Despite the relative efficacy of ablation, the risk of AF recurrence is substantial, particularly in patients with persistent AF (perAF). At present we do not have any reliable intra-procedural electrophysiologic predictors of long-term success of AF ablation other than pulmonary vein isolation.
Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. min vs. 23.76 ± 8.36 min, The rate of 12-month freedom from clinical atrial arrhythmia recurrence was 85.1%
Patients undergoing atrial fibrillation (AFib) ablation who were not properly anticoagulated and did not undergo preprocedural transesophageal echocardiogram (TEE) were significantly more likely to suffer from transient ischemic attack (TIA) or pulmonary embolism (PE).
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.
BackgroundCatheter ablation is frequently used to manage recurrent atrial fibrillation (AF) resistant to drug therapy, with pulmonary vein isolation (PVI) as a key tactic. The reconnection of pulmonary veins was discovered primarily in the anterior region of the right superior PV and the superior portion of the left superior PV.
Pulmonary vein isolation (PVI) by pulsed-field ablation (PFA) has demonstrated encouraging clinical results for the treatment of atrial fibrillation (AF)1,2. This study aims to assess procedural characteristics, safety, and clinical outcomes of PFA-based PVI in patients with a LCPV.
Abstract Introduction Some previous studies have reported that a first-step ethanol infusion into the vein of Marshall (EIVOM) with touch-up radiofrequency (RF) ablation can facilitate mitral isthmus (MI) block and improves the ablationoutcomes in persistent atrial fibrillation (PeAF) patients. 0.78, p = .006).
What are the patient characteristics, population rates, and 30-day outcomes of pulmonary vein isolation (PVI) in a nationwide sample of US adults aged >65 years?
Thermal-based ablation techniques, such as cryoballoon ablation (CBA), are widely used for pulmonary vein isolation (PVI) but show notable recurrence rates, particularly in obese patients.
Background Catheter ablation (CA) for symptomatic atrial fibrillation (AF) offers the best outcomes for patients. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation.
Pulmonary vein reconnections (PVRs) remain a concern in atrial fibrillation (AF) ablation. Eliminating PVRs during redo sessions can lead to favorable rhythm outcomes. However, the significance of PVR in AF recurrence may differ between patients who undergo additional ablation and those who do not.
While atrial fibrillation (AF) ablation has advanced to improve safety, success rates have been slower to improve. Factors contributing to this include the failure to personalize ablation strategies for individuals. 1,2) Despite this, no patient-specific factors have been consistently identified to predict either of these outcomes.
Background: Patients with atrial fibrillation (AF) and concomitant pulmonary hypertension (pHTN) have an increased risk of morbidity and mortality. However, the outcomes of catheter ablation in this cohort are unclear.
Cryoballoon (CB) ablation is the mainstay of single-shot pulmonary vein isolation (PVI). A radiofrequency balloon (RFB) catheter has recently emerged as an alternative. However, these two technologies have not been compared.
Pulmonary vein (PV) isolation is the cornerstone of radiofrequency (RF) ablation for atrial fibrillation (AF). PV reconnection is the most common cause of recurrent AF following an ablation procedure. Additionally, the relationship between impedance drop during ablation lesion delivery and PV ostial WT is not well understood.
Background The value of empirical superior vena cava isolation (SVCI) following pulmonary vein isolation (PVI) to improve the efficacy of radiofrequency catheter ablation (RFCA) for paroxysmal atrial fibrillation (PAF) remains controversial. RFCA was guided by quantitative AI in both groups. vs 81.5%, p=0.02). 95% CI 0.19
There are limited effective treatment options for persistent atrial fibrillation (AF) ablation. An epicardial-endocardial approach, combining surgical and catheter convergent radiofrequency (RF) ablation, has shown improved outcomes than an endocardial-only RF strategy.
No data have been reported on cooling characteristics and the impact of variant pulmonary vein (PV) anatomy on atrial fibrillation (AF) recurrences after POLARx cryoballoon (CB) ablation.
Abstract Introduction Although first-pass isolation (FPI) of the pulmonary vein (PV) has been suggested as a marker for PV isolation (PVI) durability, it has not been confirmed. Non-PV atrial fibrillation (AF) triggers were the main target in patients without PV reconnection in the second ablation procedure, but the outcome was unclear.
Pulmonary vein isolation is a well-established treatment for atrial fibrillation (AF). There is increasing evidence to suggest differences in outcomes between male and female patients. Despite the increasing evidence in support of catheter ablation for AF, women remain underrepresented in major clinical trials.
The concept of high-power short-duration (HPSD) radiofrequency ablation has been suggested to generate quick and efficient lesions for pulmonary vein isolation (PVI).
This study of 16 patients with persistent left superior vena cava (PLSVC) undergoing atrial fibrillation ablation shows a 66.7% identification rate of PLSVC-related triggers and an 85% success rate in acute isolation or targeted ablation. recurrence rate signals the need for enhanced outcomes in this challenging population.
Left atrial posterior wall isolation (LAPWI) plus pulmonary vein isolation (PVI) can be performed with radiofrequency ablation, cryoballoon ablation (CB-A), or, recently, pulsed field ablation (PFA).
Abstract Introduction Through systematic scientific rigor, the CLOSE guided workflow was developed and has been shown to improve pulmonary vein isolation durability. However, this technique was developed at a time when using power-controlled ablation catheters with conventional power ranges was the norm.
Ablation of regions demonstrating spatiotemporal dispersion (SD) has been demonstrated as an alternative strategy beyond pulmonary vein isolation in patients with persistent atrial fibrillation. Occurrence of atrial tachycardia (AT) following ablation remains a limitation of this approach.
Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. Data comparing PFA to VHPSD-PVI is lacking. Two tamponades occurred in the PFA while in VHPSD two pts suffered groin bleedings.
Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy. ablations over a lifetime.
Pulsed field ablation (PFA) has become increasingly important in the treatment of cardiac arrhythmias. In addition to single-shot devices mainly used for pulmonary vein isolation, focal PFA may provide a treatment option that increases the versatility of the technique.
Pulsed field ablation (PFA) is a nonthermal energy source for ablation of cardiac arrhythmias. This study investigated the prospective outcomes of a novel PFA generator in conjunction with a commercially available, contact force-sensing, focal ablation catheter.
Background The limited availability of balloon sizes for cryoballoon leads to anatomical limitations for pulmonary vein (PV) isolation. Search keywords included ‘atrial fibrillation’, ‘cryoballoon ablation’ and ‘anatomy’ Results Overall, 243 articles were identified.
ABSTRACT Background Ultra-low temperature cryoablation (ULTC) is a technique designed to rapidly cool cardiac tissue to extremely low temperatures, enabling the creation of ablation lesions for the treatment of atrial fibrillation (AF). Arrhythmia outcomes after repeat ablation were evaluated.
We present the long-term outcome of catheter ablation (CA) and electrophysiological characteristics in HIV+ AF patients. During first procedure, all received isolation of pulmonary vein (PV) + posterior wall and superior vena cava. Among patients that underwent redo ablation non-PV triggers were higher in HIV group [93.5%
Pulmonary vein isolation (PVI) using radiofrequency (RF) ablation is an established treatment strategy for atrial fibrillation (AF). Novel high-power short-duration (HPSD) ablation protocols generate an optimized lesion geometry which may translate to an improved ablation efficacy and durability.
Despite advances, catheter ablation success rates for persistent AF remain at 50-60%. The approach for recurrent persistent AF, beyond pulmonary vein isolation, remains contentious. Surgical maze procedures have demonstrated superior outcomes compared to catheter ablation.
The GANGLIA-AF trial was a prospective, multicenter, randomized, single-blinded study (NCT02487654) randomizing paroxysmal AF patients to either stand-alone left atrial ectopy-triggering GP (ET-GP) ablation or standard pulmonary vein isolation (PVI) only.1
ABSTRACT Introduction Pulmonary vein isolation (PVI) by cryoballoon ablation (CBA) is considered an effective primary strategy for early persistent atrial fibrillation (AF). The primary outcome was recurrence of atrial tachyarrhythmias (ATs) of 30-s after a 3-month blanking period. years, 80% men) underwent de novo CBA.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
40 
Let's personalize your content